

## Faslodex® (fulvestrant) - Expanded indication

- On August 28, 2107, <u>AstraZeneca announced</u> the <u>FDA approval</u> of <u>Faslodex (fulvestrant)</u> injection, for the treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy.
  - Faslodex is also approved for HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy; and treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with <a href="Ibrance">Ibrance</a> (palbociclib) in women with disease progression after endocrine therapy.
- The expanded indication approval for Faslodex was based on the <u>FALCON trial</u>, which compared Faslodex to <u>Arimidex<sup>®</sup> (anastrozole)</u> in 462 postmenopausal women with HR-positive, metastatic or locally advanced breast cancer. The primary endpoint was progression-free survival (PFS).
  - A statistically significant increase in median PFS was shown with Faslodex vs. Arimidex (16.6 months vs. 13.8 months), representing a 20% reduction in the risk of disease progression or death (HR = 0.797 [95% CI: 0.637, 0.999], p = 0.049).
- The recommended dose of Faslodex is 500 mg intramuscularly on days 1, 15, 29, and once monthly thereafter.
- Refer to the Faslodex drug label for the dosing of Ibrance when used in combination with Faslodex.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.